Abstract:INTRODUCTION: The effects of tumor-associated neutrophils (TANs) on glioblastoma biology remain poorly understood. While TANs are generally considered immunosuppressive, recent studies have demonstrated their ability to present antigen to T cells, warranting investigation of this phenotype in glioblastoma. METHODS: Flow cytometry was used to sort and characterize surface protein expression among neutrophils across 5 newly diagnosed glioblastoma fresh tissue specimens. Samples were evaluated transcriptomically via single-cell RNA sequencing (scRNA-seq) or phenotypically via coculture with autologous T cells. TANs were further evaluated in a syngeneic glioma mouse model (Balb/c), treated with either neutrophil-depleting antibody (αLy6G) or isotype control; tumor size was ascertained by bioluminescent imaging. Skull bone marrow was tagged with fluorescent dye in neutrophil tracing experiments. RESULTS: 21.0-34.1% of patient glioblastoma TANs express MHCII, a marker of antigen-presenting cells not canonically associated with neutrophils and not expressed in matched peripheral blood (PBNs). scRNA-seq pseudotime analysis demonstrates that antigen-presenting neutrophils are a developmental lineage seen uniquely in TANs and not PBNs, with enriched expression of MHCII subunits (HLA-DR), chaperones (HLA-DM), and costimulatory ligands (CD86/83;). Consequently, TANs activate T cells in an MHCII-dependent manner (CD25 MFI fold-change, PBNs vs TANs: 1.1 vs 3.2, p < 0.001), and depleting neutrophils in a murine model yields endpoint tumors that have 53% lower CD8+ T cell infiltration (n = 13, p = 0.0024) and are 2.4-fold larger (p = 0.0383). The lack of MHCII+ neutrophils in blood suggests that these cells may be recruited from local marrow niches and not circulation; indeed, in vivo, we observe that compared to all TANs, MHCII+ TANs are disproportionately derived from skull bone marrow (41.7% vs 9.3%). CONCLUSIONS: Given the recruitment of immunostimulatory TANs from the calvarium to the glioblastoma microenvironment, mechanisms to enhance neutrophil transmarrow migration may have therapeutic value.

Roles of Neutrophils in Glioma and Brain Metastases

Neutrophils in glioma microenvironment: from immune function to immunotherapy

Neutrophils: New Critical Regulators of Glioma

Brief review on the roles of neutrophils in cancer development

Rational targeting of immunosuppressive neutrophils in cancer

Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy

Microenvironmental regulation of tumor-associated neutrophils in malignant glioma: from mechanism to therapy

[Neutrophils in the tumor microenvironment-foes or friends?]

Role of Neutrophils on Cancer Cells and Other Immune Cells in the Tumor Microenvironment

Tumor-associated neutrophils and neutrophil-targeted cancer therapies

Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies

Targeting and Exploitation of Tumor-Associated Neutrophils to Enhance Immunotherapy and Drug Delivery for Cancer Treatment

Tumor-Associated Neutrophils in Cancer: Going Pro

Neutrophils in cancer: dual roles through intercellular interactions

Multifaceted Roles of Neutrophils in Tumor Microenvironment

Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms

Immune microenvironment landscape and the role of neutrophils in glioblastoma

The local microenvironment drives activation of neutrophils in human brain tumors

A Review on How Neutrophils Are Related With Cancer Metastasis

Cancer‐related circulating and tumor‐associated neutrophils – subtypes, sources and function

517 Glioblastoma Induces the Recruitment of Anti-Tumoral Immunostimulatory Neutrophils from Skull Bone Marrow